Primecap Management Co. CA Has $57.97 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Primecap Management Co. CA decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 294,989 shares of the medical research company’s stock after selling 30,967 shares during the quarter. Primecap Management Co. CA’s holdings in IQVIA were worth $57,968,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IQV. Raymond James Financial Inc. acquired a new position in IQVIA during the 4th quarter worth $236,120,000. FMR LLC lifted its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the 3rd quarter worth $147,683,000. JPMorgan Chase & Co. lifted its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $188.45 on Wednesday. The company has a fifty day moving average price of $196.06 and a 200 day moving average price of $209.52. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $256.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $33.23 billion, a PE ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on IQV shares. Barclays dropped their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, UBS Group dropped their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.